Evaluating N-acetylcysteine efficacy in the prevention of amphotericin B-induced nephrotoxicity

Not Applicable

• Conditions: Fungal infections.; Certain infectious and parasitic diseases; B37? B38 ?

• Registration Number: IRCT201107233449N8
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1- Age between 18 to 65 years
2- Hemodynamica stability (Mean arterial pressure > 70 mmHg and Systolic blood pressure > 90 mmHg)
3- Receiving AmB for treatment of fungal infections

Exclusion criteria
1- Documented history of acute kidney injury or chronic kidney disease
2- The status of kidney function at baseline is unknown
3- Receiving N-acetylcysteine (oral or parenteral) recently (during the last 1 month)
4- Documented history of hypersensitivity/anaphylactic reactions to N-acetylcysteine
5- Co-administration of antioxidants (e.g. vitamin E, vitamin C)

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ephrotoxicity. Timepoint: At baseline then weekly. Method of measurement: renal function tests (BUN, Cr), serum electrolytes and biomarkers (cystatine C and KIM-1).